Related Experiment Video
Updated: Jul 15, 2025
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Immunotherapeutic strategy in the management of gastric cancer: molecular profiles, current practice, and ongoing
Mengxiao Lu1, Yingjie Wu2, Yixin Zhang2
1Department of Gastrointestinal Minimally Invasive Surgery, The Affiliated People's Hospital of Ningbo University, Ningbo, China. 2111105139@nbu.edu.cn.
Abstract:
Gastric cancer (GC) is the one of the most commonly solid cancer worldwide. Although under the aggressive treatment, the poor clinical outcomes of patients with GCs have not been improved. Current studies emphasized that targeting therapies or immune response-based therapeutic strategy may be a potential approach to improve the clinical outcomes. Moreover, accumulative evidence has reported the increasing expression of PD-L1 expression in GC cells and highlighted its role in the tumor progression. Currently, great development has been established in the immune checkpoint inhibitors (ICIs) and further changed the clinical practice of GC treatment and prognosis. In addition, the combination therapies with targeting therapy or traditional therapies are expected to push the development of immunotherapies. In our present review, we predominantly focus on the biomarkers and molecular profiles for immunotherapies in GCs and highlight the role and administration of ICIs-based immunotherapeutic strategies against the GCs.
Insights
Gastric cancer (GC) treatment is improving with immune checkpoint inhibitors (ICIs). This review focuses on biomarkers and molecular profiles for effective immunotherapy strategies in GC patients.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Gastric cancer (GC) remains a leading global cancer with poor outcomes despite aggressive treatments.
- Increasing PD-L1 expression in GC cells is linked to tumor progression.
- Immune checkpoint inhibitors (ICIs) represent a promising therapeutic avenue for GC.
Purpose of the Study:
- To review biomarkers and molecular profiles for immunotherapy in GC.
- To highlight the role and administration of ICIs-based strategies for GC.
- To explore combination therapies to advance GC immunotherapies.
Main Methods:
- Literature review focusing on immunotherapy in gastric cancer.
- Analysis of biomarkers and molecular profiles relevant to GC immunotherapies.
- Evaluation of immune checkpoint inhibitors (ICIs) and combination strategies.
Main Results:
- PD-L1 expression is a key factor in GC progression and response to immunotherapy.
- ICIs have significantly altered GC treatment paradigms and prognosis.
- Combination therapies show potential for enhancing immunotherapeutic efficacy in GC.
Conclusions:
- Biomarkers and molecular profiling are crucial for optimizing immunotherapy in GC.
- ICIs represent a significant advancement in GC treatment.
- Further research into combination strategies is essential for improving GC patient outcomes.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...